Name
Chronic myelomonocytic leukemia
ICD-O-1 Morphology
9863/3: Chronic myeloid leukemia, NOS
Effective
1978 - 1991
ICD-O-2 Morphology
9868/3: Chronic myelomonocytic leukemia
Effective
1992 - 2000
ICD-O-3 Morphology
9945/3: Chronic myelomonocytic leukemia
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
The peripheral blood and bone marrow are always involved. The spleen, liver, skin and lymph nodes are the most common sites of extramedullary infiltration. The peripheral blood has persistent monocytosis. There are fewer than 20% blasts in the peripheral blood and bone marrow.
The physician will run tests to exclude the BCR-ABL1 fusion gene, the rearrangement of PDGFRA or PDGFRB. The physician uses the information from these tests to do a diagnosis of exclusion (clinical diagnosis) of Chronic myelomonocytic leukemia.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_6
The physician will run tests to exclude the BCR-ABL1 fusion gene, the rearrangement of PDGFRA or PDGFRB. The physician uses the information from these tests to do a diagnosis of exclusion (clinical diagnosis) of Chronic myelomonocytic leukemia.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_6
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Chronic myelomonocytic leukemia-0
Chronic myelomonocytic leukemia-1
Chronic myelomonocytic leukemia-2
Chronic myelomonocytic leukemia, NOS
Chronic myelomonocytic leukemia, Type I
Chronic myelomonocytic leukemia, Type II
Chronic myelomonocytic syndrome
CMML
CMML with eosinophilia
CMML-1
CMML-2
CMMoL
Subacute myelomonocytic leukemia
Definition
CMML is a clonal disorder of a bone marrow stem cell, in which monocytosis is a major defining feature. The clinical, hematologic and morphologic features of CMML are heterogeneous, and vary along a spectrum from predominantly myelodysplastic to mainly myeloproliferative in nature.
A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone marrow, crowding out other normal blood cells, such as white blood cells, red blood cells and platelets. Also called chronic myelomonocytic leukemia.
A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone marrow, crowding out other normal blood cells, such as white blood cells, red blood cells and platelets. Also called chronic myelomonocytic leukemia.
Definitive Diagnostic Methods
Bone marrow biopsy
Clinical diagnosis
Genetic testing
Immunophenotyping
Peripheral blood smear
Genetics Data
Immunophenotyping
CD13+ (expression/positive)
CD33+ (expression/positive)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
Transformations from
None
Same Primaries
Corresponding ICD-9 Codes
206.1 Chronic monocytic leukemia
Corresponding ICD-10 Codes
C93.1 Chronic monocytic leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C93.1 Chronic myelomonocytic leukemia (effective October 01, 2015)
Signs and Symptoms
Diagnostic Exams
Blood chemistry studies
Bone marrow aspiration and biopsy
Cytogenetic analysis
Immunocytochemistry
Peripheral blood smear
Progression and Transformation
Transformation to AML occurs in ~15-30% of cases
Epidemiology and Mortality
Age: 65-75 years median age
Incidence: 12.8 cases per 100,000 persons per year
Sex: male predominance
Survival: 20-40 months median survival
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 82-86
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 82-86
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1
Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1